2.61
-0.12(-4.40%)
Currency In USD
| Previous Close | 2.73 |
| Open | 2.73 |
| Day High | 2.8 |
| Day Low | 2.6 |
| 52-Week High | 42.2 |
| 52-Week Low | 2.23 |
| Volume | 737,342 |
| Average Volume | 2.18M |
| Market Cap | 126.08M |
| PE | -1.79 |
| EPS | -1.46 |
| Moving Average 50 Days | 2.56 |
| Moving Average 200 Days | 15.99 |
| Change | -0.12 |
If you invested $1000 in Cassava Sciences, Inc. (SAVA) 10 years ago, it would be worth $1,572.29 as of March 14, 2025 at a share price of $2.61. Whereas If you bought $1000 worth of Cassava Sciences, Inc. (SAVA) shares 5 years ago, it would be worth $4,590.46 as of March 14, 2025 at a share price of $2.61.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Cassava Sciences Licenses Simufilam Method of Treatment Patent
GlobeNewswire Inc.
Feb 27, 2025 12:00 PM GMT
Cassava enters into a license agreement with Yale University granting intellectual property rights, including rights to an issued US method of treatment patent for potential treatment with simufilam of seizures related to rare neurodevelopmental diso
Cassava Sciences Provides a Business Update
GlobeNewswire Inc.
Jan 07, 2025 9:30 PM GMT
Topline data from Phase 3 REFOCUS-ALZ study of simufilam in patients with mild-to-moderate Alzheimer’s disease expected late first-quarter/early second-quarter 2025 Implementing cost curtailment including a workforce reduction of approximately 33% A
Cassava Sciences Topline Phase 3 Data Did Not Meet Co-Primary Endpoints
GlobeNewswire Inc.
Nov 25, 2024 12:30 PM GMT
Simufilam did not show a significant reduction in cognitive or functional decline versus placebo in patients with mild-to-moderate Alzheimer’s disease in the ReThink-ALZ Phase 3 study Simufilam continued to demonstrate an overall favorable safety pro